INNOVA CAPTAB LIMITED Financial Ratios
INNOVACAP · Healthcare · Current price ₹962.7
P/E ratio
39.1x
P/B ratio
5.1x
ROE
13.7%
ROCE
15.0%
Debt / Equity
0.32
Dividend yield
0.2%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 39.1x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 5.1x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 13.7% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 15.0% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.32 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with INNOVA CAPTAB LIMITED's latest numbers.
INNOVA CAPTAB LIMITED profitability
INNOVA CAPTAB LIMITED generates a return on equity of 13.7% and a return on capital employed of 15.0%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.32 and a P/E of 39.1x, INNOVA CAPTAB LIMITED is conservatively financed. Our overall business-quality score for the company is 4.6 / 10.
Understand the ratios
More on INNOVA CAPTAB LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.